QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
Rhea-AI Summary
QuidelOrtho (Nasdaq: QDEL) will report fourth quarter and full-year 2025 financial results for the period ended December 28, 2025, after market close on Wednesday, February 11, 2026. A conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET the same day, with presentation materials and a replay available in the Events & Presentations section of the company's Investor Relations website.
Investors can join the live webcast via the IR site or by phone at 833-470-1428 (U.S.) or +1 929-526-1599 (international) using Conference ID 690468.
Positive
- None.
Negative
- None.
News Market Reaction – QDEL
In the Jan 21 session, QDEL declined 10.11%, reflecting a significant negative market reaction. Argus tracked a trough of -13.4% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-12-18 | R&D podcast | Positive | -3.6% | Science Bytes episode on advanced cardiac and GI diagnostics innovation. |
| 2025-11-24 | Investor conferences | Positive | +9.2% | Participation in two December 2025 healthcare investor conferences. |
| 2025-11-20 | Clinical podcast | Positive | +1.5% | Podcast on early detection and biomarkers in diabetes prevention. |
| 2025-11-18 | Product launch | Positive | +0.8% | Launch of QUICKVUE Influenza + SARS rapid combo test in the U.S. |
| 2025-11-05 | Earnings report | Positive | +0.9% | Q3 2025 results with adjusted profitability and narrowed full-year guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news has generally seen positive price alignment, with only one notable divergence on a positive R&D-focused update.
Over the last few months, QuidelOrtho has highlighted R&D advances, commercial execution, and capital structure changes. Podcasts on topics like high-sensitivity troponin and diabetes prevention and the launch of the QUICKVUE Influenza + SARS Test underscored product and scientific depth. Q3 2025 results showed $700M revenue, significant goodwill impairment, and narrowed full-year guidance. Investor conference participation in early December 2025 coincided with a 9.16% price gain. Today’s earnings-date announcement fits into this ongoing cadence of communications.
Key Terms
in vitro diagnostics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com. Presentation materials will also be posted to the "Events & Presentations" section of the "Investor Relations" page of the Company's website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 690468.
A replay of the conference call will be available shortly after the event on the "Investor Relations" page of the Company's website under the "Events & Presentations" section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-to-report-fourth-quarter-and-full-year-2025-financial-results-302666238.html
SOURCE QuidelOrtho Corporation